Cipla Q2 Results: Revenue from operations increased 6% year-on-year to Rs 7,051 crore in July-September 2024, up from Rs 6,678 crore in the same period last year. The company reported a 12% year-on-year EBITDA growth to Rs 1,886 crore in Q2. The One India business grew 5% YoY, with the Branded Prescription segment continuing to outperform the market in major chronic therapies.
| Subscribe To Our Free Newsletter |
